News

Video

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Dr. Elias K. Mai presents final progression-free survival results from the Phase 3 GMMG-HD7 trial, demonstrating that adding isatuximab to lenalidomide, bortezomib, and dexamethasone (Isa-RVd) significantly improves minimal residual disease negativity and reduces the risk of progression or death in transplant-eligible patients with newly diagnosed multiple myeloma.

Related Videos
YI LIN, MD, PHD
Pooja Phull, MD
4 experts are featured in this series.
4 experts are featured in this series.
Michael R. Bishop, MD
C. Ola Landgren, MD, PhD
CDAC CLL
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss ongoing research to watch in acute lymphoblastic leukemia.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss how to incorporate blinatumomab into clinical practice for ALL.